ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m
ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m
3 May 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that the Company will be attending the International Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May in San Francisco, California.
Priority focus now on Exosome drug delivery technology & Partnerships Ophthalmology assets to be out-licensed
Progression with Fosun Pharma underscores commitment to CTX stroke disability programme
11 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that Dr Randolph Corteling will re-join ReNeuron on 3 March 2022, heading up the Research team as Vice President of Research and will report directly into the CEO.
30 November 2021: ReNeuron Group plc (AIM: RENE), a UK based leader in Stem Cell and Exosome Technologies, announces its interim results for the six months ended 30 September 2021.
19 November 2021: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that new data relating to its CTX-derived induced Pluripotent Stem Cell (“CTX-iPSC”) platform has been presented this week, showing their commercial potential for the development of mass-scale therapeutics for peripheral nerve repair.
ReNeuron collaborates with UCL to generate anti-cancer immune cells for cancer therapies
Oxford University Hospitals NHS Foundation Trust activated as ReNeuron’s first UK study site
Significantly improved delivery of functional proteins to the brain demonstrated in vivo